Clinical Trials Logo
  1. Home
  2. Solid Tumour
  3. NCT01226407

Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

Solid Tumour Clinical Trial

Official title:
Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer

Clinical Trial Summary

Open label, single dose and phase I study.

The primary objective: To determine the maximum tolerated dose in Single dose

The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.

Clinical Trial Description

1. Number of Subjects: 28~36, dose escalation (2~6 subject of each step)

2. Adverse Events will be coded to preferred therm and body system using the CTCAE ;

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01226407
Study type Interventional
Source CrystalGenomics, Inc.
Contact Tae Won Kim, MD, PhD
Email twkimmd@amc.seoul.kr
Status Recruiting
Phase Phase 1
Start date September 2010
Completion date February 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02648490 - An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Phase 1
Withdrawn NCT04891718 - CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia Early Phase 1
Completed NCT01447732 - Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT04958226 - A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours Phase 1
Completed NCT04121910 - A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole Phase 1
Terminated NCT01219543 - A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase. Phase 1
Completed NCT01627990 - Nivestim™ in Treatment of Malignant Diseases N/A
Completed NCT01489826 - A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours Phase 1
Terminated NCT01516645 - Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors Phase 1
Unknown status NCT01046461 - Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer Phase 2
Completed NCT02086721 - Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor Phase 1
Active, not recruiting NCT00467779 - Study of GDC-0973/XL518 in Patients With Solid Tumors Phase 1
Completed NCT01300468 - Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors Phase 1